Skip to search formSkip to main content

H1299 Tumor Cell Lysate Vaccine

Known as: H1299 Lysate Vaccine 
A cell lysate derived from a lung cancer cell line, H1299, with potential immunostimulatory and antineoplastic activities. Upon intramuscular… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Agarosa diisolasi dari agar Gracilaria gigas. Agarosa hasil isolasi diperoleh dari agar dengan melarutkan agar dalam propilen… Expand
Is this relevant?
2016
2016
Kanker paru merupakan salah satu jenis kanker yang mempunyai tingkat insidensi yang tinggi di dunia, sebanyak 17% insidensi… Expand
Is this relevant?
2015
2015
The current study aimed to investigate effects of ethanol extract of white sesame seed (WSE) as well as a major constituent of… Expand
Is this relevant?
2014
2014
Lung cancer remains the most common cause of cancer-related death worldwide and it continues to lack effective treatment. The… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
2012
2012
Chemotherapy is one major approach for treating non-small cell lung carcinoma (NSCLC). However, the progression-free survival… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Mutations in the TP53 gene commonly result in the expression of a full-length protein that drives cancer cell invasion and… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2005
2005
최근 고령화 사회가 진행되어 가면서 폐암환자에서도 수술에 적응이 되지 않는 고령의 환자가 점차 증가하는 추세를 보이고 있어 독성이 적은 치료방법의 개발에 대한 필요성이 증가되고 있다. 따라서 기존의 항암제에 비하여 비교적 안정적으로 사용이 가능할 것으로 생각되는 선택적인 COX-2 억제제인 Nimesulide를 처치하여 COX-2 발현 유무와 COX-2 억제제가 비소세포폐암에 미치는 세포독성과의 상관관계를 연구하였다. 대상 및 방법: A549, H1299 비소세포폐암 세포주에서 COX-2 단백질에 대한 면역조직화학염 색을 시행하였으며, Nimesulide 처치후 XTT 분석, FACS 분석, Hoechst 33258 염색을 시행하였다. 결과: COX-2 단백질의 면역조직화학염색결과 A549 비소세포폐암 세포주는 COX-2 단백질에 강한 발현을 나타낸 반면, H1299 비소세포폐암 세포주는 발현을 나타내지 않았다. XTT 분석결과 Nimesulide의 A549, H1299 비소세포폐암 세포주에 대한 세포독성은 유사하였으며, Nimesulide의 $IC_{50}$ 은 A549 비소세포폐암 세포주에서는 $70.9 {\mu}M$ 이었으며, H1299 비소세포폐암 세포주에서는 $56.5 {\mu}M$ 이었다. FACS 분석에서는 각각의 세포군에서 $G_0/G_1$ 기에서 세포주기의 지연이 관찰되었으며, S기의 세포는 감소되었다. Hoechst 33258 염색에서는 양군에서 세포핵의 주변부 농축 현상 및 핵 분절을 가진 많은 사멸세포가 관찰되었다. 걸론: 선택적인 COX-2억제제인 Nimesulide는 비소세포폐암 세포주에서 암세포의 증식을 억제함을 알 수 있었으며, 암세포증식 억제의 기전은 세포자멸사의 유도와 $G_0/G_1$ 기에서 세포주기의 지연임을 알 수 있었으며, COX-2의 발현유무와 세포독성은 차이가 없는 것을 알 수 있었다. 따라서 Nimesulide와 같은 선택적인 COX-2 억제제는 다양한 항암제나 방사선치료와 병행하여 고위험군의 폐암환자에서 매우 효과적으로 사용될 수 있을 것으로 기대된다. 【In recent years, a combination of two demographic phenomena, an increased number of older people in the population and an increase in the incidence of lung cancer with age, has made it mandatory to develop therapeutic modalities with less toxicity for the treatment of inoperable elderly patients with lung cancer. Therefore, we investigated the correlation between COX-2 expression and cytotoxicity of Nimesulide, a specific COX-2 inhibitor. Material and Method: Immunohistochemical staining of COX-2 was performed. After exposure of Nimesulide, XTT analysis, FACS analysis and Hoechst staining were carried out. Result: COX-2 protein was expressed in non-treated A549 cells strongly, but not in H1299. Cytotoxicity of Nimesulide against A549 cell and H1299 cell were similar and $IC_{50}$ of Nimesulide in both cell lines were $70.9{\mu}M$ in A549 cell line and $56.5{\mu}M$ in H1299 cell line respectively. FACS analysis showed $G_0/G_1$ arrest in both cell lines and the S phase cell fraction was decreased. Morphologic assessment of apoptosis by Hoechst 33258 staining, many apoptotic cells were detected in both cell lines. Conclusion: Selective COX-2 inhibitor, Nimesulide, can inhibit the proliferation of non-small cell lung cancer cell lines in vitro. Inhibitory effect of Nimesulide are induction of apoptosis and $G_0/G_1$ arrest. There is no correlation between COX-2 expression and cytotoxicity of Nimesulide, a specific COX-2 inhibitor. Therefore, highly selective COX-2 inhibitors such as Nimesulide can be expected to lead to even greater efficacy of their use as adjuncts to various anticancer angents and radiation therapy for the treatment of high-risk patients.】 
Is this relevant?
2003
2003
BACKGROUND MBD2 is a methylated DNA-binding protein that has been previously suggested to have transcriptional silencing as well… Expand
Is this relevant?